An international group of researchers based in Boston and China studied over 190,000 people for an average of 25 years, ...

KANSAS CITY, Kan., March 26, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...

Shares of CING opened at $3.96 on Friday. Cingulate has a fifty-two week low of $1.80 and a fifty-two week high of $20.83. The firm has a 50-day simple moving average of $4.34 and a 200-day simple ...

The latest analyst rating for Cingulate (NASDAQ:CING) was provided by HC Wainwright & Co., and Cingulate reiterated their buy rating. The last upgrade for Cingulate Inc happened on November 20 ...

In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date ...

In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for ...

Huang and colleagues examined neural responses in mouse anterior cingulate cortex (ACC) during a discrimination-avoidance task. The authors present useful findings that ACC neurons encode primarily ...